Single Cell Proteomics

Cancer immunotherapy, which includes adoptive cell transfer (ACT) for immune cells and monoclonal antibody (mAb) treatment, is a way to treat cancer by modifying an immune response. Immunoregulatory pathway blockage or activation, which is the basis of mAb therapy's stimulation of T cell function, has produced notable therapeutic responses in a range of tumor types. After therapy, some individuals may not be able to sustain a robust immune response. 

The immune system's diversity and dynamism present numerous difficulties for contemporary cancer treatments. It has proven challenging to conduct proteomics based on cell populations in order to advance our understanding of how tumor cells interact with the immune system. We provide a thorough analysis of systemic immunity and the tumor microenvironment using single-cell proteomics in order to obtain further knowledge for cancer immunotherapy. Through the systematic analysis of protein levels in numerous single cells within the immune system and tumor microenvironment, single-cell proteomics platform allows for the direct evaluation of immune cell function and tumor-immune interactions. This information can be utilized to evaluate the effectiveness of immunotherapy and enhance clinical results.